GlaxoSmithKline's Tykerb fails in gastric cancer trial; Boehringer, Lilly unveil diabetes-management game;

@FiercePharma: FDA close to resolving all cancer drug shortages; most stem from production halts to fix manufacturing issues. More | Follow @FiercePharma

@EricPFierce: ICYMI: Dr. Reddy's, Fujifilm pull plug on Japanese joint venture. Article | Follow @EricPFierce

@CarlyHFierce: European Commission to crack down on 'pay for delay,' reportedly fine 9 companies including Lundbeck, Merck KGaA, Ranbaxy. Article | Follow @CarlyHFierce

> GlaxoSmithKline's ($GSK) breast cancer drug Tykerb doesn''t boost survival rates in patients with gastric cancer compared with chemo alone, study finds. Report

> Boehringer Ingelheim and Eli Lilly ($LLY) launched an educational digital game to teach desktop and iPad users the importance of managing Type 2 diabetes. Report

> Courts in Ireland and the U.S. temporarily blocked Royalty Pharma's bid for Elan ($ELN). Report

> Adcock Ingram, the South African drugmaker that's up for sale, saw profits decline by 5.4% in the quarter. Report

Medical Device News

@FierceMedDev: Stryker confronts mounting metal hip recall lawsuits. Story | Follow @FierceMedDev

@DamianFierce: St. Jude is targeting FDA approval for its renal denervation device with a new study. Report | Follow @DamianFierce

@MarkHFierce: Get your FMD Fierce 15 nominations in today. | Follow @MarkHFierce

@MichaelGFierce: ICYMI yesterday: Medtronic triggers summer PMA process for drug-eluting balloon. Story | Follow @MichaelGFierce

> Medtronic wins FDA nod, CE mark for angioplasty balloon. Story

> Zimmer boosts bone biz with German buyout. News

> Canon revs up MA med tech R&D operation. Report

>  U of Minnesota fires competitive blast with new med devices center. Item

Biotech News

@FierceBiotech: Trending: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

 @JohnCFierce: Remember the Pluristem scandal last fall? FDA clamps clinical hold on Pluristem PhII stem cell trial. More | Follow @JohnCFierce

@RyanMFierce: J&J backs $biotech startup Protagonist in $14M financing. News | Follow @RyanMFierce

> FDA clamps clinical hold on Pluristem PhII stem cell trial. News

> R&D: Are true drug breakthroughs a thing of the past? More

> AstraZeneca tosses another PhIII failure onto the scrap heap. Report

> Akebia snags $41M financing in anemia-drug race with GlaxoSmithKline, others. Article

> Cardio3 tests Europe's appetite for biotech IPOs. Item

Biotech Research News

@EmilyMFierce: Alterations in one gene may drive allergic, autoimmune diseases. Story | Follow @EmilyMFierce

> $750,000 in grants available to scientific researchers under new program. Report

> NIH lays out effects of sequestration on biomedical research. News

> New agent stops replication of hep C virus in preclinical studies. Article

> Pfizer taps UCSF for small-molecule drug discovery. Story

Pharma Manufacturing News

> CorePharma gets closeout letter for NJ plant. Report

> WSJ: Novartis looks to unload CMO LTS Lohmann. Article

> FDA close to resolving all cancer drug shortages. Story

> Explosion, fire at Teva plant kills one, injures 30. More

And Finally... Long-term cancer survivors need special treatment and often aren't getting it. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.